A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection

Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals

(2022) Ying Zhao et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature

(2022) Sarah M Rowe et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe

(2022) Barbara Rossetti et al.   HIV MEDICINE

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

(2022) Sinead Delany-Moretlwe et al.   LANCET

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

(2022) Theodore D Ruel et al.   Lancet HIV

Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration

(2022) Clémence Richetta et al.   JOURNAL OF VIROLOGY

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

(2022) Bastian Neesgaard et al.   Lancet HIV

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations

(2021) Yuta Hikichi et al.   mBio

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

(2021) Kirsten L. White et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants

(2021) Steven J. Smith et al.   ACS Infectious Diseases

Mutations in the HIV-1 3′-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance

(2021) Yuliang Wei et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

(2021) Chloe Orkin et al.   Lancet HIV

Long-acting cabotegravir + rilpivirine for HIV-1 treatment

(2021) Susan Swindells et al.   AIDS

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

(2021) Raphael J. Landovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Forgiveness of dolutegravir-based triple therapy compared to older antiretroviral regimens: a prospective multicenter cohort of adherence patterns and HIV-RNA replication

(2021) Jean-Jacques Parienti et al.   Open Forum Infectious Diseases

Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer

(2021) Pia-Allison E Roa et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

(2021) Emma M Kileel et al.   Open Forum Infectious Diseases

Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis

(2020) Sarah E Moore et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

(2020) Chloe Orkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis for strand-transfer inhibitor binding to HIV intasomes

(2020) Dario Oliveira Passos et al.   SCIENCE

Structural basis of second-generation HIV integrase inhibitor action and viral resistance

(2020) Nicola J. Cook et al.   SCIENCE

Comparative Clinical Pharmacokinetics a1 nd Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

(2020) Anthony T. Podany et al.   CLINICAL PHARMACOKINETICS

Outcomes of Integrase Inhibitor–based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection

(2020) Matthew E. Levy et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada

(2020) Kassem Bourgi et al.   Journal of the International AIDS Society

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study

(2020) Axel Ursenbach et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

(2020) A. Gaillet et al.   MEDECINE ET MALADIES INFECTIEUSES

Mitochondrial DNA haplogroups and weight gain following switch to INSTI-Based ART

(2020) Kristine M. Erlandson et al.   AIDS

Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV

(2020) Cecile D. Lahiri et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting

(2019) Thibaut Davy-Mendez et al.   AIDS

Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle

(2019) Rachel Van Duyne et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

(2019) Olga Kaplun et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana

(2019) Rebecca Zash et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir Use at Conception — Additional Surveillance Data from Botswana

(2019) Mmakgomo M. Raesima et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting

(2019) Kai Juhani Kauppinen et al.   AIDS PATIENT CARE AND STDS

Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations

(2019) Francesco Saladini et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection

(2019) Pedro Cahn et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries

(2018) Marco Vitoria et al.   AIDS

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection

(2018) Pedro Cahn et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure

(2018) Marieke Roskam-Kwint et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

(2018) Ingeborg E A Wijting et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

(2018) Steven J. Smith et al.   Retrovirology

Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception

(2018) Rebecca Zash et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

538. Integrase Inhibitor-Based HAART Is Associated with Greater BMI Gains in Blacks, Hispanics, and Women

(2018) Roger Bedimo et al.   Open Forum Infectious Diseases

Brief Report

(2017) Mieke Jongbloed-de Hoon et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2017) José R. Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Psychiatric Symptoms in Patients Receiving Dolutegravir

(2017) Anna Fettiplace et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

(2017) Isabelle Malet et al.   mBio

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

(2017) Catherine Orrell et al.   Lancet HIV

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

(2017) Pedro Cahn et al.   Lancet HIV

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)

(2017) Joseph Custodio et al.   Open Forum Infectious Diseases

Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection

(2016) L. Buscemi   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study

(2016) Kathleen Squires et al.   Lancet HIV

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

(2015) José R. Santos et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of the impact of multivalent metal ions on the permeation behavior of Dolutegravir sodium

(2015) Julia Anita Grießinger et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Brief Report

(2015) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

(2015) Anthony Mills et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2015) Sharon Walmsley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

(2015) Slim Fourati et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents

(2015) Rolando M. Viani et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

(2015) Melinda J. Reese et al.   XENOBIOTICA

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

(2015) Gary David Bowers et al.   XENOBIOTICA

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

(2014) Rujuta A Bam et al.   ANTIVIRAL THERAPY

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

(2014) Bisher Akil et al.   ANTIVIRAL THERAPY

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

(2014) Paul E. Sax et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

(2014) Ivy Song et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults

(2014) Karen Tashima et al.   Journal of the International AIDS Society

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

(2014) Jean-Michel Molina et al.   Journal of the International AIDS Society

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment

(2014) Donna Sweet et al.   Journal of the International AIDS Society

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects

(2014) Jian Zong et al.   Journal of the International AIDS Society

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

(2014) Karen Tashima et al.   AIDS Research and Therapy

Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012

(2013) Christopher B. Hurt et al.   CLINICAL INFECTIOUS DISEASES

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection

(2013) Andrew Zolopa et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) David A. Wohl et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) Nathan Clumeck et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics

(2013) Felix DeAnda et al.   PLoS One

HIV: Cell Binding and Entry

(2013) C. B. Wilen et al.   Cold Spring Harbor Perspectives in Medicine

Evolution of HIV integrase resistance mutations

(2012) Peter K. Quashie et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function

(2012) Polina German et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Exploring the Molecular Mechanism of Cross-Resistance to HIV-1 Integrase Strand Transfer Inhibitors by Molecular Dynamics Simulation and Residue Interaction Network Analysis

(2012) Weiwei Xue et al.   Journal of Chemical Information and Modeling

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

(2011) Richard Elion et al.   AIDS

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

(2011) Kendra E. Hightower et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

(2011) S. Hare et al.   MOLECULAR PHARMACOLOGY

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

(2011) Alex Sigal et al.   NATURE

Potencial de los inhibidores de la integrasa para deplecionar los reservorios o para impedir que se rellenen

(2010) Josep M. Llibre et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Retroviral intasome assembly and inhibition of DNA strand transfer

(2010) Stephen Hare et al.   NATURE

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance

(2010) S. Hare et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell-to-Cell Spread of Retroviruses

(2010) Quentin J. Sattentau   Viruses-Basel

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Exacerbation of depression associated with starting raltegravir: a report of four cases

(2008) Marianne Harris et al.   AIDS

Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

(2008) AA Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection

(2008) Jean-Michel Molina   DRUGS